A randomized phase III study on the effect of bortezomib combined with adriamycin [doxorubicin], dexamethasone (AD) for induction treatment, followed by high dose melphalan and bortezomib alone during maintenance in patients with multiple myeloma.

Next Previous
Trial Profile

A randomized phase III study on the effect of bortezomib combined with adriamycin [doxorubicin], dexamethasone (AD) for induction treatment, followed by high dose melphalan and bortezomib alone during maintenance in patients with multiple myeloma.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Apr 2016

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone; Doxorubicin; Melphalan; Thalidomide; Vincristine
  • Indications Multiple myeloma
  • Focus Adverse reactions; Pharmacogenomic; Registrational; Therapeutic Use
  • Sponsors Millennium

    • Most Recent Events

    • 08 Apr 2016 Pooled pharmacogenomics genome-wide association study analysis (n=598) of 3 trials [IFM 2005-01, IFM2007-02, and HOVON-65/GMMG-HD4 ] were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 08 Dec 2015 Results of long term follow up presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
    • 09 Dec 2013 Results after extended follow-up (median 67 months) presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top